Galderma @ EADV 2023: Phase III Trials Demonstrate Nemolizumab’s Efficacy and Rapid Onset of Action in Atopic Dermatitis and Prurigo Nodularis

ZUG, Switzerland--(BUSINESS WIRE)--Galderma announced positive data from three pivotal phase III trials in atopic dermatitis and prurigo nodularis – ARCADIA 1 and 2 and OLYMPIA 1, respectively. The late-breaking data were presented today at the 2023 European Academy of Dermatology and Venereology (EADV) congress in Berlin. The ARCADIA 1 and 2 trials met their co-primary and all key secondary endpoints, demonstrating that nemolizumab significantly reduced skin lesions and itch in patients with a